Skinvisible (SKVI) Stock Price, News & Analysis

Company Overview

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

Key Stats

• Today's Range: $0.31 to $0.31
• 50-Day Range: $0.27 to $0.58
• 52-Week Range: $0.06 to $0.85
• Volume: 200 shs
• Average Volume: 1,500 shs
• Market Capitalization: $1.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Skinvisible Stock Analysis - MarketRank™

Skinvisible scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Skinvisible.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Skinvisible is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Skinvisible is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Skinvisible has been sold short.

Short Interest Ratio / Days to Cover

Skinvisible has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Skinvisible does not currently pay a dividend.

Dividend Growth

Skinvisible does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the float of Skinvisible has been sold short.

Short Interest Ratio / Days to Cover

Skinvisible has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.7 / 5
• News Sentiment: N/A

News Sentiment

Skinvisible has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Skinvisible this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Skinvisible insiders have not sold or bought any company stock.

Percentage Held by Insiders

53.00% of the stock of Skinvisible is held by insiders. A high percentage of insider ownership can be a sign of company health.

SKVI Stock Analysis - Frequently Asked Questions

How have SKVI shares performed this year?

Skinvisible's stock was trading at $0.3370 on January 1st, 2025. Since then, SKVI stock has decreased by 8.8% and is now trading at $0.3072.
View the best growth stocks for 2025 here.

How do I buy shares of Skinvisible?

Shares of SKVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Skinvisible own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Skinvisible investors own include Angus Energy (ANGS), HEXO (HEXO), Bunker Hill Mining (BHLL), Blue Dolphin Energy (BDCO), American Power Group (APGI), Advanced Oxygen Technologies (AOXY) and Aeolus Pharmaceuticals (AOLS).

Company Calendar

• Today: 4/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SKVI
• CIK: 1085277
• Web: www.skinvisible.com
• Phone: (702) 433-7154
• Fax: 702-433-7192
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,380,000.00
• Net Margins: -5,920.00%
• Pretax Margin: -5,915.00%
• Return on Equity: N/A
• Return on Assets: -754.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.01
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: $20,000.00
• Price / Sales: 83.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.99) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 5,404,000
• Free Float: 2,540,000
• Market Cap: $1.66 million
• Optionable: Not Optionable
• Beta: 0.26